Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted psychotherapy for generalized anxiety disorder
ACTRN12621001358831Phase 2Completed
- Sponsor
- Monash University
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of psilocybin in generalized anxiety disorder (GAD) (2 arms), sponsored by Monash University. Primary endpoint: Change in Hamilton Anxiety Ratings Scale (HAM-A) at Week 11. Started May 2022; status: completed.
02
Drugs
psilocybin
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on ACTRN12621001358831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001358831.